347 related articles for article (PubMed ID: 32409308)
21. Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging.
Li D; Zou S; Cheng S; Song S; Wang P; Zhu X
Mol Pharm; 2019 Aug; 16(8):3469-3476. PubMed ID: 31283253
[TBL] [Abstract][Full Text] [Related]
22. Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors.
Beckford Vera DR; Smith CC; Bixby LM; Glatt DM; Dunn SS; Saito R; Kim WY; Serody JS; Vincent BG; Parrott MC
PLoS One; 2018; 13(3):e0193832. PubMed ID: 29513764
[TBL] [Abstract][Full Text] [Related]
23. Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB.
Dudal S; Hinton H; Giusti AM; Bacac M; Muller M; Fauti T; Colombetti S; Heckel T; Giroud N; Klein C; Umaña P; Benincosa L; Bachl J; Singer T; Bray-French K
J Immunother; 2016 Sep; 39(7):279-89. PubMed ID: 27404941
[TBL] [Abstract][Full Text] [Related]
24. ImmunoPET imaging of tissue factor expression in pancreatic cancer with
Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W
J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831
[TBL] [Abstract][Full Text] [Related]
25. JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.
Leclercq G; Haegel H; Toso A; Zimmermann T; Green L; Steinhoff N; Sam J; Pulko V; Schneider A; Giusti AM; Challier J; Freimoser-Grundschober A; Larivière L; Odermatt A; Stern M; Umana P; Bacac M; Klein C
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064010
[TBL] [Abstract][Full Text] [Related]
26.
Moek KL; Waaijer SJH; Kok IC; Suurs FV; Brouwers AH; Menke-van der Houven van Oordt CW; Wind TT; Gietema JA; Schröder CP; Mahesh SVK; Jorritsma-Smit A; Lub-de Hooge MN; Fehrmann RSN; de Groot DJA; de Vries EGE
Clin Cancer Res; 2019 Jun; 25(12):3517-3527. PubMed ID: 30745297
[TBL] [Abstract][Full Text] [Related]
27. Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor Immunity.
Stoltzfus CR; Sivakumar R; Kunz L; Olin Pope BE; Menietti E; Speziale D; Adelfio R; Bacac M; Colombetti S; Perro M; Gerner MY
Front Immunol; 2021; 12():726492. PubMed ID: 34421928
[TBL] [Abstract][Full Text] [Related]
28. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
[TBL] [Abstract][Full Text] [Related]
29. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.
Osada T; Patel SP; Hammond SA; Osada K; Morse MA; Lyerly HK
Cancer Immunol Immunother; 2015 Jun; 64(6):677-88. PubMed ID: 25742933
[TBL] [Abstract][Full Text] [Related]
30. Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers.
Teijeira A; Migueliz I; Garasa S; Karanikas V; Luri C; Cirella A; Olivera I; Cañamero M; Alvarez M; Ochoa MC; Rouzaut A; Rodriguez-Ruiz ME; Sanmamed MF; Klein C; Umaña P; Ponz M; Bacac M; Melero I
Theranostics; 2022; 12(3):1373-1387. PubMed ID: 35154495
[No Abstract] [Full Text] [Related]
31. Preclinical development of ZED8, an
Ogasawara A; Kiefer JR; Gill H; Chiang E; Sriraman S; Ferl GZ; Ziai J; Bohorquez SS; Guelman S; Wang X; Yang J; Phan MM; Nguyen V; Chung S; Yu C; Tinianow J; Waaijer SJH; De Crespigny A; Marik J; Boswell CA; Zabka T; Staflin K; Williams SP
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):287-301. PubMed ID: 36271158
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer.
Stergiou N; Nagel J; Pektor S; Heimes AS; Jäkel J; Brenner W; Schmidt M; Miederer M; Kunz H; Roesch F; Schmitt E
Int J Med Sci; 2019; 16(9):1188-1198. PubMed ID: 31588183
[TBL] [Abstract][Full Text] [Related]
33. Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
Hornig N; Kermer V; Frey K; Diebolder P; Kontermann RE; Müller D
J Immunother; 2012 Jun; 35(5):418-29. PubMed ID: 22576347
[TBL] [Abstract][Full Text] [Related]
34. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
[TBL] [Abstract][Full Text] [Related]
35. Immuno-PET of Murine T Cell Reconstitution Postadoptive Stem Cell Transplantation Using Anti-CD4 and Anti-CD8 Cys-Diabodies.
Tavaré R; McCracken MN; Zettlitz KA; Salazar FB; Olafsen T; Witte ON; Wu AM
J Nucl Med; 2015 Aug; 56(8):1258-64. PubMed ID: 25952734
[TBL] [Abstract][Full Text] [Related]
36. Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab.
Jagoda EM; Lang L; Bhadrasetty V; Histed S; Williams M; Kramer-Marek G; Mena E; Rosenblum L; Marik J; Tinianow JN; Merchant M; Szajek L; Paik C; Cecchi F; Raffensperger K; Jose-Dizon JM; Bottaro DP; Choyke P
J Nucl Med; 2012 Oct; 53(10):1592-600. PubMed ID: 22917884
[TBL] [Abstract][Full Text] [Related]
37. Development of
Kol A; Fan X; Wazynska MA; van Duijnhoven SMJ; Giesen D; Plat A; Van Eenennaam H; Elsinga PH; Nijman HW; de Bruyn M
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600560
[TBL] [Abstract][Full Text] [Related]
38. [
Gallegos CA; Lu Y; Clements JC; Song PN; Lynch SE; Mascioni A; Jia F; Hartman YE; Massicano AVF; Houson HA; Lapi SE; Warram JM; Markert JM; Sorace AG
Theranostics; 2024; 14(3):911-923. PubMed ID: 38250045
[No Abstract] [Full Text] [Related]
39. Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.
Fan D; Li W; Yang Y; Zhang X; Zhang Q; Yan Y; Yang M; Wang J; Xiong D
J Hematol Oncol; 2015 Oct; 8():108. PubMed ID: 26444983
[TBL] [Abstract][Full Text] [Related]
40. CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.
Sam J; Hofer T; Kuettel C; Claus C; Thom J; Herter S; Georges G; Korfi K; Lechmann M; Eigenmann MJ; Marbach D; Jamois C; Lechner K; Krishnan SM; Gaillard B; Marinho J; Kronenberg S; Kunz L; Wilson S; Briner S; Gebhardt S; Varol A; Appelt B; Nicolini V; Speziale D; Bez M; Bommer E; Eckmann J; Hage C; Limani F; Jenni S; Schoenle A; Le Clech M; Vallier JP; Colombetti S; Bacac M; Gasser S; Klein C; Umaña P
Blood; 2024 May; 143(21):2152-2165. PubMed ID: 38437725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]